investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
The Role of Fgf Signaling in Vertebrate Development
Mark Lewandoski
1 Collaborator(s)
Funding source
National Cancer Institute (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Determine role of FGF3 signaling in axis extension
Related projects
Kent Hunter
Genetic Modifiers of Initiation and Progression of Mammary Cancer
Breast
Gregory Longmore
Novel Small Molecule Inhibition of DDR2 to Prevent Breast Cancer Metastasis
Breast
Roger W Howell
Radiation induced bystander effects in radium-223 therapy
Breast
Radiation Oncology
Hans Schreiber
Immunology of Unique Tumor Specific Antigens
Prostate
Breast
Li Xin
The Notch Signaling in Prostate Homeostasis and Carcinogenesis
Prostate
Mien-Chie Hung
Nuclear EGFR in Cancer Cell Signaling and Radioresistance
Breast
Radiation Oncology
Rakesh Kumar
Pak1 Signaling and Targets in Breast Cancer Progression
Breast
William C Hahn
Regulation and function of IKKe in breast cancer initiation and maintenance
Breast
Pathology
Powel Brown
A MULTICENTER PHASE II STUDY OF DOCOSAHEXAENOIC ACID IN PATIENTS WITH A HISTORY OF BREAST CANCER, PREMALIGNANT LESIONS, OR BENIGN BREAST DISEASE
Breast
